These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18448761)

  • 1. A once-yearly IV bisphosphonate for osteoporosis.
    Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
    [No Abstract]   [Full Text] [Related]  

  • 2. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 3. Consultation corner. Bone loss drug gives users a break.
    Bellantoni M
    Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
    [No Abstract]   [Full Text] [Related]  

  • 4. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. By the way, doctor. Should I take an intravenous drug for osteoporosis?
    Robb-Nicholson C
    Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
    [No Abstract]   [Full Text] [Related]  

  • 7. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
    Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I
    Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
    [No Abstract]   [Full Text] [Related]  

  • 10. New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life.
    Duke Med Health News; 2007 Dec; 13(12):8. PubMed ID: 18286732
    [No Abstract]   [Full Text] [Related]  

  • 11. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD
    MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
    [No Abstract]   [Full Text] [Related]  

  • 12. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 13. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
    Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
    [No Abstract]   [Full Text] [Related]  

  • 14. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
    Atik OS
    Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
    [No Abstract]   [Full Text] [Related]  

  • 15. Sore mandible. Bisphosphonate-associated osteonecrosis.
    Damm DD; Fantasia JE
    Gen Dent; 2006; 54(5):370, 372. PubMed ID: 17004575
    [No Abstract]   [Full Text] [Related]  

  • 16. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 17. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
    Konsta M; Bournia VK; Dania V; Iliopoulos A
    J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
    [No Abstract]   [Full Text] [Related]  

  • 18. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
    Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
    [No Abstract]   [Full Text] [Related]  

  • 19. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD; Nitschmann S
    Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.